journal
MENU ▼
Read by QxMD icon Read
search

Journal of Oncology Pharmacy Practice

journal
https://www.readbyqxmd.com/read/28162029/should-mannitol-be-reinstated-in-prevention-of-cisplatin-induced-nephrotoxicity
#1
Jean-Philippe Adam, Marie-Andrée Fournier, Nathalie Letarte
No abstract text is available yet for this article.
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28147928/pembrolizumab-induced-myasthenia-gravis-a-fatal-case-report
#2
Katherine L March, Michael J Samarin, Amik Sodhi, Ryan E Owens
Purpose Pembrolizumab, a monoclonal antibody which inhibits the programmed cell death 1 receptor, has been shown to efficaciously enhance pre-existing immune responses to malignancies. However, safety concerns must also be considered as pembrolizumab use has been associated with several life-threatening immune-related adverse events (irAEs). We report a fatal case of pembrolizumab-induced myasthenia gravis in a patient with no prior myasthenia gravis history. Case report A 63-year-old male presented with right eyelid drooping, puffiness, blurred vision, and shortness of breath two weeks after an initial infusion of pembrolizumab...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28147927/a-case-report-of-enzalutamide-administration-in-a-dialysis-dependent-patient-with-castration-resistant-prostate-cancer
#3
Erica S Tsang, Marie de Haan, Bernhard J Eigl
Enzalutamide, an androgen receptor signaling inhibitor, is a standard of care treatment for metastatic castration-resistant prostate cancer. We present the first reported case of enzalutamide in a patient with end-stage renal disease, on dialysis. While there were no significant toxicities, a sustained increase in systolic blood pressure was maintained after starting enzalutamide, suggestive of a degree of drug accumulation. Further evaluation of novel hormonal agents in end-stage renal disease patients should be encouraged as this population is typically excluded from clinical trials...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28077048/baxter-elastomeric-pumps-weighing-as-an-alternative-to-visual-inspection
#4
Ellen L Cusano, Raafi Ali, Michael B Sawyer, Carole R Chambers, Patricia A Tang
Purpose Elastomeric pumps are used to administer 46-hour infusions of 5-fluorouracil (5FU). Baxter suggests patients visually monitor their pumps to ensure that infusions are proceeding correctly. This can be confusing and lead to concerns about under- or over-dosing. Baxter has not considered weighing pumps as a validated method for monitoring. This study aims to validate weighing as a more accurate method for patients and healthcare professionals, and describe real life Baxter Infusor™ variability. Methods Patients who had been started on a 46-hour 5FU infusion returned to the clinic approximately 24 h after starting treatment...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28077047/extended-infusion-compared-to-standard-infusion-cefepime-as-empiric-treatment-of-febrile-neutropenia
#5
Rebekah H Wrenn, David Cluck, LeAnne Kennedy, Christopher Ohl, John C Williamson
Background Extended infusion (EI) dosing provides a longer time above the minimum inhibitory concentration, which is important for the clinical success of β-lactam antibiotics, especially for patients with impaired immunity. The aim of this study was to determine the feasibility and clinical impact of administering cefepime by EI as treatment of febrile neutropenia. Methods This was a prospective, randomized, comparative pilot study. All patients received cefepime 2 g IV every 8 h, with the first dose administered using a 30-min infusion...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28077046/rational-use-of-rasburicase-for-the-treatment-and-management-of-tumor-lysis-syndrome
#6
Suhail A Shaikh, Bernard L Marini, Shannon M Hough, Anthony J Perissinotti
Purpose There is a lack of high-level evidence identifying meaningful outcomes and the optimal place in therapy of rasburicase in patients with, or at high risk for tumor lysis syndrome. The primary objective of this study was to evaluate and characterize outcomes resulting from an institution-specific guideline emphasizing supportive care, xanthine oxidase inhibitors, and lower doses of rasburicase. Methods In this retrospective chart review, we compared conservative rasburicase dosing, in accordance with newly developed UMHS tumor lysis syndrome guidelines, with aggressive rasburicase in adult patients (≥ 18 years of age) with hematological or solid tumor malignancies, and a uric acid level between 8 and 15 mg/dL...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28077045/association-of-time-to-antibiotics-and-clinical-outcomes-in-adult-hematologic-malignancy-patients-with-febrile-neutropenia
#7
Allison R Butts, Christina Carracedo Bachmeier, Emily V Dressler, Meng Liu, Ann Cowden, Jeff Talbert, Val R Adams
Objective The objective of this study was to determine the clinical impact of time to antibiotic administration in adult inpatients who have hematologic malignancies and develop febrile neutropenia. Methods A retrospective chart review was conducted to screen for all febrile neutropenia events amongst adult hematologic malignancy patients between 1 January 2010 and 1 September 2014. All included patients were admitted to the hospital at the time of fever onset, having been admitted for a diagnosis other than febrile neutropenia...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26970573/ibrutinib-associated-tumor-lysis-syndrome-in-a-patient-with-mantle-cell-lymphoma-a-case-report
#8
Varinder Kaur, Arjun Swami
Mantle cell lymphoma accounts for 5-7% of all non-Hodgkin's lymphomas. Under the current WHO classification, it is categorized as an indolent B cell lymphoma, but has an aggressive clinical course. New insights into leukemogenic molecular pathways of mantle cell lymphoma have uncovered unique therapeutic targets. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is the newest drug in the arsenal that has shown promising efficacy in relapsed mantle cell lymphoma. Long-term studies have shown that grade 3 or 4 adverse events are infrequent...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26946531/late-onset-pericardial-tamponade-bilateral-pleural-effusions-and-recurrent-immune-monoarthritis-induced-by-ipilimumab-use-for-metastatic-melanoma
#9
Constantin A Dasanu, Tiffany Jen, Ryszard Skulski
While an important agent in the contemporary anti-melanoma armamentarium, ipilimumab is associated with serious immune reactions including late immune-mediated side effects. Recently, a case of late-onset acute pericarditis with tamponade was reported at 12 weeks after the last dose of ipilimumab. While polyarthralgia rheumatica has been previously documented with ipilimumab, we were not able to find any reports of recurrent monoarthritis with the use of this agent. Therefore, we present herein a unique case featuring a patient with late-onset autoimmune pleuropericarditis leading to cardiac tamponade at 24 weeks post-ipilimumab and recurrent late immune knee arthritis at 8 and 32 weeks, respectively...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26911479/irinotecan-induced-dysarthria-a-case-report-and-review-of-the-literature
#10
Krista G Ramirez, Marla D Koch, William J Edenfield
Irinotecan-induced dysarthria has been reported in the literature, but the underlying mechanism of this neurotoxicity remains unclear. Here, we present a 35-year-old female with metastatic colon cancer who experienced dysarthria during irinotecan infusion. Her symptoms were decreased and eventually eliminated with subsequent increases in infusion time. When the patient returned to original 90 min infusion time, symptoms were significantly reduced in both severity and duration as compared to the first infusion...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26911477/flipped-script-for-gefitinib-a-reapproved-tyrosine-kinase-inhibitor-for-first-line-treatment-of-epidermal-growth-factor-receptor-mutation-positive-metastatic-nonsmall-cell-lung-cancer
#11
Brian S Bogdanowicz, Matthew A Hoch, Megan E Hartranft
Purpose The approval history, pharmacology, pharmacokinetics, clinical trials, efficacy, dosing recommendations, drug interactions, safety, place in therapy, and economic considerations of gefitinib are reviewed. Summary Lung cancer is one of the most commonly diagnosed cancers and is the leading cause of cancer death. Platinum-based chemotherapy and tyrosine kinase inhibitors, such as erlotinib and afatinib, are recommended therapies for nonsmall cell lung cancer. The European Medicines Association based their approval of gefitinib on the randomized, multicenter Iressa Pan-Asia Study (IPASS, NCT00322452) and a single-arm study showing effectiveness in Caucasians (IFUM, NCT01203917)...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26864940/healthcare-resource-use-and-costs-associated-with-renal-impairment-in-us-patients-with-bone-metastases-from-solid-tumors
#12
Yi Qian, Jorge Arellano, Debajyoti Bhowmik, Erin Thomson, David M Smith, Guy Hechmati, Xue Song
Introduction During cancer progression, more than half of patients develop renal insufficiency, including chronic kidney disease. The primary and secondary objectives of this study were to estimate healthcare resource use and costs, respectively, associated with renal impairment in patients with bone metastases from solid tumors in the United States. Methods and materials This was a retrospective, observational cohort study conducted using administrative claims data for individuals with solid tumors and bone metastases...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26854267/pharmacists-roles-in-oncology-pharmacy-services-results-of-a-global-survey
#13
Lisa M Holle, Christy S Harris, Alexandre Chan, Rebecca J Fahrenbruch, Bonnie A Labdi, Jocelyn E Mohs, Leann B Norris, Janelle Perkins, Cory M Vela
Background Oncology pharmacists are capable of providing medication therapy management (MTM) because of their level of training, practice experiences, and responsibilities. Very little data exist about their current practice, including changing roles in the multidisciplinary team, overall impact, and effects in the education of patients and healthcare professionals. Methods A 70-item survey about oncology pharmacists' activities in oral chemotherapy programs, MTM, and collaborative practice agreements (CPAs) was deployed using a web survey tool (Qualtrics, Provo, UT, USA), targeting pharmacist members of American College of Clinical Pharmacy (ACCP) Hematology/Oncology Practice and Research Network (PRN)...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26854266/safety-of-anticoagulation-in-thrombocytopenic-patients-with-hematologic-malignancies-a-case-series
#14
Peter M Campbell, Cindy Ippoliti, Sapna Parmar
The incidence of venous thromboembolism is greater among cancer patients than the general patient population, with recurrence rates also much higher in patients with cancer diagnoses. Patients with hematologic malignancies often experience prolonged periods of thrombocytopenia throughout their disease course, making therapeutic anticoagulation a challenge. We describe 13 cases of patients with hematologic malignancies that were therapeutically anticoagulated with either low-molecular-weight heparin or unfractionated heparin during periods of severe thrombocytopenia (platelet counts < 50 × 10(9)/µL)...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26830549/incidence-of-hypocalcemia-in-patients-receiving-denosumab-for-prevention-of-skeletal-related-events-in-bone-metastasis
#15
Prakirthi Yerram, Shraddha Kansagra, Osama Abdelghany
Background Denosumab therapy is commonly used for the prevention of skeletal-related events in patients with bone metastasis. However, a common side effect of denosumab is hypocalcemia. Objective The aim of the study is to determine the incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis and evaluate risk factors for developing hypocalcemia. Methods This was a retrospective medication use evaluation reviewing the incidence of hypocalcemia in patients receiving outpatient denosumab for prevention of skeletal-related events at Yale-New Haven Hospital...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26811403/response-of-metastatic-mucosal-melanoma-to-immunotherapy-it-can-get-worse-before-it-gets-better
#16
Shebli Atrash, Issam Makhoul, Jason S Mizell, Laura Hutchins, Fade Mahmoud
Immune therapy with checkpoint inhibitors has revolutionized the management of metastatic melanoma. Ipilimumab, nivolumab, and pembrolizumab are all FDA-approved immune checkpoint inhibitors to treat metastatic melanoma. Responses to immune checkpoint inhibitors are usually delayed. An interim progression on restaging computed tomography scans "pseudo-progression" may be observed before response to treatment occur. In this case, we report a significant interim progression of metastatic mucosal melanoma before meaningful responses to immunotherapy occurred...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26786027/high-versus-low-dose-leucovorin-in-the-modified-folfox6-regimen-for-first-line-treatment-of-metastatic-colorectal-cancer
#17
Jana Reynolds, April Chamberland-Tremblay, Jon D Herrington, Yolanda Munoz Maldonado, Lucas Wong
Background In response to the national leucovorin shortage in 2008, our institution adjusted the modified FOLFOX6 (leucovorin, fluorouracil, and oxaliplatin) protocol to utilize a lower dose of leucovorin (20 mg/m(2)). This adjustment was based on prospective studies suggesting that lower doses of leucovorin may be equally effective in other fluorouracil containing regimens. This retrospective study evaluates outcomes in metastatic colorectal cancer (mCRC) patients treated with low- (20 mg/m(2)) vs. high-dose (400 mg/m(2)) leucovorin in the FOLFOX6 regimen for mCRC...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26763004/effects-of-the-leucovorin-shortage-pilot-study-investigating-cost-efficacy-and-toxicity-comparison-of-low-fixed-dose-versus-body-surface-area-adjusted-leucovorin-dosing-in-patients-with-resectable-colon-or-metastatic-colorectal-cancer
#18
Brandon R Shank, Amy H Seung, Katharine Kinsman, Matthew J Newman, Ross C Donehower, Bradley Burton
Purpose As a result of the leucovorin shortage, we switched from BSA-adjusted to low fixed-dose leucovorin in patients with colon cancer receiving fluorouracil-containing therapy. Methods A retrospective, pilot study of adults receiving intravenous leucovorin as part of a fluorouracil-containing treatment was conducted including individuals with stage II or III colon or newly diagnosed metastatic colorectal cancer. One low fixed-dose (leucovorin 50 mg) patient was matched by the investigator to one BSA-adjusted (leucovorin 200-500 mg/m(2)/dose) patient on disease stage and age...
April 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26811404/taxane-induced-arthralgia-and-myalgia-a-literature-review
#19
Nicholas Chiu, Leonard Chiu, Ronald Chow, Henry Lam, Sunil Verma, Mark Pasetka, Edward Chow, Carlo DeAngelis
Purpose Arthralgia and myalgia following taxane chemotherapy has been documented in the literature. However, these two toxicities associated with taxane treatment have not been closely examined in the literature, and data remain inconsistent in terms of the reported incidences of these toxicities. The purpose of this literature review was to provide a more comprehensive understanding of the incidence of taxane-induced arthralgia and myalgia, as well as to document the risk factors and preventative and therapeutic treatments that have been investigated...
January 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26763003/rifampin-sirolimus-voriconazole-interaction-in-a-hematopoietic-cell-transplant-recipient
#20
Justin A Wasko, James S Westholder, Pamala A Jacobson
Purpose Patients undergoing hematopoietic cell transplantation are treated with multiple medications, potentially complicated by drug-drug interactions. Drug interactions with sirolimus, voriconazole, and rifampin are particularly difficult because of the complex and simultaneous enzyme inhibition and induction mechanisms. We report a hematopoietic cell transplantation patient receiving sirolimus and voriconazole who was given rifampin while being treated for presumed methicillin-resistant Staphylococcus aureus meningitis...
January 2017: Journal of Oncology Pharmacy Practice
journal
journal
32324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"